The bill amends the New Jersey Menopause Coverage Act to include testosterone therapy as a covered treatment for women experiencing perimenopause and menopause. It mandates that all health insurance carriers, including hospital service corporations, medical service corporations, health maintenance organizations, and various health benefit plans, provide coverage for testosterone therapy on par with other hormonal treatments. Importantly, the bill stipulates that coverage cannot be denied based on the FDA approval status of the therapy for these specific conditions, thereby enhancing access to necessary treatments for women during these transitional phases.

Additionally, the legislation requires that clear and accessible information regarding covered treatments for perimenopause and menopause be provided to insured individuals. It emphasizes comprehensive care, which includes both hormonal and non-hormonal treatments, behavioral health services, and preventative measures. The bill also introduces definitions for menopause and perimenopause to clarify the medical criteria for these conditions. The provisions will take effect 90 days after enactment and will apply to policies and contracts issued or renewed thereafter, ensuring that women receive adequate support during this critical stage of life.

Statutes affected:
Introduced: 17:48-6, 17:48A-7, 17:48E-35.52, 17B:26-2.1, 17B:27-46.1, 26:2J-4.53, 17B:27A-7.36, 52:14-17.29, 52:14-17.46.6, 30:4D-6